SEC Company Response from NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Dec 18, 2008

NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Dec. 18, 2008 · CIK: 0000906709 · Accession: 0001144204-08-069937

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 000-24006

Referenced dates: December 10, 2008

Date

Dec. 18, 2008

Author

/s/

Form

CORRESP

Company

NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)

Letter

Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attention: Nandini Acharya, Esq. Re: Nektar Therapeutics. -- Form 10-K for the Year Ended December 31, 2007 (File No. 000-24006)

Dear Ms. Acharya:

We are in receipt of the letter dated December 10, 2008 (the “Comment Letter”), including comments from the staff of the Securities and Exchange Commission to the Form 10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation, on February 29, 2008.

We will provide a response to the Comment Letter no later than January 16, 2009.

Please do not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma, Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at (650) 473-2670, regarding this matter.

Sincerely,
/s/
Gil M. Labrucherie

Show Raw Text

CORRESP
1
filename1.htm

    Nektar
Therapeutics

    201
Industrial Road

    San
Carlos, California 94070

    Sender
Contact Information

    P: (650)
620-5990

    F: (650)
620-5360

    December
18, 2008

    VIA FACSIMILE AND U.S.
MAIL

    Securities
and Exchange Commission

    Division
of Corporate Finance

    Washington,
D.C.  20549

    Attention:  Nandini
Acharya, Esq.

              Re:

              Nektar Therapeutics.
      -- Form 10-K for the Year Ended December 31, 2007 (File No.
      000-24006)

    Dear Ms.
Acharya:

    We are in
receipt of the letter dated December 10, 2008 (the “Comment Letter”), including
comments from the staff of the Securities and Exchange Commission to the Form
10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar
Therapeutics, a Delaware corporation, on February 29, 2008.

    We will
provide a response to the Comment Letter no later than January 16,
2009.

    Please do
not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma,
Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at
(650) 473-2670, regarding this matter.

              Sincerely,

              /s/
      Gil M. Labrucherie

              Gil
      M. Labrucherie

              Senior
      Vice President, General Counsel & Secretary of Nektar
      Therapeutics

                cc:

              Howard
      W. Robin, President and Chief Executive Officer of Nektar
      Therapeutics

                Sam
      Zucker, Esq., O’Melveny & Myers
LLP

              Jennifer
      A. DePalma, Esq., O’Melveny & Myers
LLP

SecProbe.io